Cargando…

Antisense oligonucleotides extend survival of prion-infected mice

Prion disease is a fatal, incurable neurodegenerative disease of humans and other mammals caused by conversion of cellular prion protein (PrP(C)) into a self-propagating neurotoxic conformer (prions; PrP(Sc)). Strong genetic proofs of concept support lowering PrP expression as a therapeutic strategy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raymond, Gregory J., Zhao, Hien Tran, Race, Brent, Raymond, Lynne D., Williams, Katie, Swayze, Eric E., Graffam, Samantha, Le, Jason, Caron, Tyler, Stathopoulos, Jacquelyn, O’Keefe, Rhonda, Lubke, Lori L., Reidenbach, Andrew G., Kraus, Allison, Schreiber, Stuart L., Mazur, Curt, Cabin, Deborah E., Carroll, Jeffrey B., Minikel, Eric Vallabh, Kordasiewicz, Holly, Caughey, Byron, Vallabh, Sonia M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777807/ https://www.ncbi.nlm.nih.gov/pubmed/31361599 http://dx.doi.org/10.1172/jci.insight.131175

Ejemplares similares

Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
por: Reidenbach, Andrew G., et al.
Publicado: (2019)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

A single-cell map of antisense oligonucleotide activity in the brain
por: Mortberg, Meredith A, et al.
Publicado: (2023)

Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints
por: Minikel, Eric Vallabh, et al.
Publicado: (2020)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Regional variability and genotypic and pharmacodynamic effects on PrP concentration in the CNS
por: Mortberg, Meredith A., et al.
Publicado: (2022)

The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration
por: Jafar-nejad, Paymaan, et al.
Publicado: (2020)

Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system
por: Sullivan, Jenna M., et al.
Publicado: (2020)

Analysis of non-human primate models for evaluating prion disease therapeutic efficacy
por: Mortberg, Meredith A., et al.
Publicado: (2022)

Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials
por: Mortberg, Meredith A., et al.
Publicado: (2022)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2017)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model
por: Zhao, Hien Tran, et al.
Publicado: (2021)

Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy
por: Watt, Andrew T., et al.
Publicado: (2020)

An Antisense Oligonucleotide Leads to Suppressed Transcription of Hdac2 and Long-Term Memory Enhancement
por: Poplawski, Shane G., et al.
Publicado: (2020)

Therapeutic Trial of anle138b in Mouse Models of Genetic Prion Disease
por: Vallabh, Sonia M., et al.
Publicado: (2023)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021)

Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
por: Chappell, Alfred E, et al.
Publicado: (2020)

Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
por: Østergaard, Michael E., et al.
Publicado: (2013)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides
por: Østergaard, Michael E., et al.
Publicado: (2017)

Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
por: Seth, Punit P, et al.
Publicado: (2012)

Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
por: Prakash, Thazha P, et al.
Publicado: (2019)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
por: Skotte, Niels H., et al.
Publicado: (2014)

Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
por: Swayze, Eric E., et al.
Publicado: (2007)

Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017)

Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
por: Qiao, Yuanyuan, et al.
Publicado: (2023)

Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models
por: Moore, Lauren R., et al.
Publicado: (2017)

Elucidation of the Biotransformation Pathways of a Galnac(3)-conjugated Antisense Oligonucleotide in Rats and Monkeys
por: Shemesh, Colby S, et al.
Publicado: (2016)

Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
por: Østergaard, Michael E, et al.
Publicado: (2020)

Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
por: Wan, W. Brad, et al.
Publicado: (2014)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Antisense Oligonucleotide Therapeutic Approach for Suppression of Ataxin-1 Expression: A Safety Assessment
por: O’Callaghan, Brennon, et al.
Publicado: (2020)

Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
por: Mummery, Catherine J., et al.
Publicado: (2023)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u1tu392okbhrnt606hgjrro5nt